Successes in Bone Marrow Failures
This program is sponsored by the Cleveland Clinic Center for Continuing Education and supported by Aplastic Anemia & MDS International Foundation, Inc.
| Location: |
San Diego Marriott Marquis & Marina, Marriott Hall |
| Speakers: |
David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA
Ramon Tiu, MD, PhD, Cleveland Clinic, Cleveland, OH
Valerie Santini, MD, University of Florence, Florence, Italy
Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Antonio Risitano, MD, PhD, Federico II University Medical School, Naples, Italy
Bart Scott, MD, Fred Hutchinson Cancer Center, Seattle, WA
|
This symposium will focus on providing an in-depth and up-to-date review of research related to the biology and clinical management of myelodysplastic syndromes (MDS) and other bone marrow failure diseases. The overall goal of the program is to bring together leaders in research and clinical practice to explore solutions to improving the care of these patient populations.
Contact: Roberta Stavole, Cleveland Clinic Center for Continuing Education
Phone: 216-448-0789
E-mail:stavolr@ccf.org
back to top
The Road to a Cure of Chronic Lymphocytic Leukemia (CLL)
This program is sponsored by MedEDirect LLC and supported by CLL Global Research Foundation.
| Location: |
San Diego Convention Center, Room 6A |
| Speakers: |
Susan O'Brien, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Stefan Stilgenbauer, MD, University of Ulm, Ulm, Germany
John Gribben, MD, Barts Cancer Center of Excellence/The London School of Medicine, London, United Kingdom
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
William Plunkett, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
Carlo Croce, MD, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH
|
This symposium will focus on current issues with chronic lymphocytic leukemia (CLL), including the significant development of effective treatments such as chemoimmunotherapy, which is illustrated by the recent approval of fludarabine, cyclophosphamide, rituxumab (FCR) regimen, monoclonal antibodies, and stem cell transplantation as feasible treatment methods. This educational intervention will address the related uncertainty these advances have created in the minds of hematologists and oncologists as to the current state of clinical decision making in CLL. These evidence-based, didactic presentations will include some discussions with illustrative case examples where appropriate.
Contact: Tipp Nelson, World Health Communications US
Phone: 214-213-7057
E-mail: tipp@worldhealthcommunications.com
back to top
Gynecologic Challenges for Hematologists: Tools for Optimal Management of Women and Adolescent Girls with Blood Disorders
This program is sponsored by Duke University and supported by the Foundation for Women & Girls with Blood Disorders.
| Location: |
San Diego Marriott Marquis & Marina, San Diego Ballroom |
| Speakers: |
Andra James, MD, Duke University Medical Center, Durham, NC
Roshni Kulkarni, MD, Michigan State University, East Lansing, MI
Jennifer E. Dietrich, MD, Baylor College of Medicine, Houston, TX
Peter Kouides, MD, Lipson Cancer and Blood Center, Rochester General Hospital, Rochester, NY
Kim Smith-Whitley, MD, The Children's Hospital of Philadelphia, Philadelphia, PA
|
This symposium will focus on providing evidence-based information on the clinical management of menorrhagia in women and adolescent girls with blood disorders. By assembling thought leaders from disciplines integral to the development and dissemination of effective management guidelines, this session will present state-of-the-art gynecologic information relevant to hematologists who treat women and girls.
Contact: Ann-Marie Nazzaro, Foundation for Women & Girls with Blood Disorders
Phone: 646-265-7489
E-mail:amnazzaro@fwgbd.org
back to top
Current Clinical Controversies and Future Research Priorities for the Treatment of Multiple Myeloma
This program is sponsored by The Center for Biomedical Continuing Education and supported by Multiple Myeloma Research Foundation, Celgene Corporation, Lilly USA, LLC, Novartis Pharmaceuticals Corporation, and Millennium Pharmaceuticals, Inc.
| Location: |
San Diego Convention Center, Room 6DE |
| Speakers: |
Paul G. Richardson, MD, Dana-Farber Cancer Institute, Boston, MA
Herve Avet-Loiseau, MD, PhD, University Hospital of Nantes, Nantes, France
Andrzej J. Jakubowiak, MD, PhD, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain
Philip McCarthy Jr., MD, Roswell Park Cancer Institute
|
This symposium will bring together clinical experts to share their perspectives on the current clinical controversies and future research priorities for the treatment of multiple myeloma. The program will utilize various methods of participation to engage attendees and enhance the learning process, including compelling faculty presentations, three clinical cases from community hematologists/oncologists, an interactive case panel discussion/debate about each case, an audience response system, and an audience question-and-answer session.
Contact: Anne Quinn Young, MPH, The Center for Biomedical Continuing Education
Phone: 203-652-0212
E-mail:quinnyounga@themmrf.org
back to top
Next-Generation Approaches for Evaluation and Treatment of Myelodysplastic Syndromes (MDS)
This program is sponsored by Educational Review Systems and supported by MDS Foundation.
| Location: |
Manchester Grand Hyatt San Diego, Elizabeth Ballroom |
| Speakers: |
Peter Greenberg, MD, Stanford University Medical Center, Palo Alto, CA
Alan List, MD, H. Lee Moffitt Cancer Center, Tampa, FL
Jacqueline Boultwood, MD, University of Oxford, Oxford, United Kingdom
Ghulam Mufti, DM, King's College Hospital, London, United Kingdom
Juliet N. Barker, MD, Memorial Sloan Kettering Cancer Center, New York, NY
|
This symposium will focus on updated prognostic assessment of MDS, the revised International Prognostic Scoring System (IPSS-R), molecular characterization of MDS risk and predisposition, and ribosome function and molecular biology of the 5q-syndrome. This symposium will also focus on combinational therapy and use of newer agents in MDS, as well as advances in hematopoietic stem cell transplantation for MDS such as umbilical cord blood transplants and reduced intensity conditioning.
Contact: Tracey Iraca, MDS Foundation
Phone: 609-298-1600
E-mail:tiraca@mds-foundation.org
back to top
Recent Advances in Hematopoietic Cell Transplantation: Evidence-Based Decision Making
This program is sponsored by the Medical College of Wisconsin and supported by the National Marrow Donor Program.
| Location: |
San Diego Convention Center, Ballroom 20AB |
| Speakers: |
Dennis Confer, MD, National Marrow Donor Program, Minneapolis, MN
John Wingard, MD, Shands Cancer Hospital, University of Florida, Gainesville, FL
Willis Navarro, MD, National Marrow Donor Program, Minneapolis, MN
Helen Heslop, MD, Baylor College of Medicine, Houston, TX
|
This session will succinctly describe the results and impact of recent clinical research that has shaped transplant decision making from both U.S. and international efforts. Presenters will also provide an overview of the importance of donor search strategies on transplant timing and outcomes. Looking to the future, clinicians will also learn about upcoming clinical trials using cellular therapy that may impact post-transplant care.
Contact: Renee Ryan, National Marrow Donor Program
Phone: 612-884-8430
E-mail:rryan@nmdp.org
back to top
Innovations in Laboratory Medicine: Therapeutic Assessment
This program is sponsored by the Cleveland Clinic Center for Continuing Education and supported by the Wallace H. Coulter Foundation.
| Location: |
Manchester Grand Hyatt San Diego, Manchester Ballroom |
| Speakers: |
Shannon M. Bates, MDCM, McMaster University, Hamilton, Ontario, Canada
Charles S. Eby, MD, Washington University School of Medicine, St. Louis, MO
Dorothy M. (Adcock) Funk, MD, Esotorix, Inc., Phoenix, AZ
Richard D. Press, MD, PhD, Oregon Health & Science University, Portland, OR
Garry P. Nolan, PhD, Stanford School of Medicine, Stanford, CA
|
Innovations in laboratory medicine play an important role in all stages of therapeutic decision making, from whom to treat and what therapy to select, to how that therapy should be monitored. This symposium gathers five international experts who will discuss the optimal application of laboratory testing in addressing recognized clinical dilemmas, including predicting risk of venous thromboembolism in patients with cancer, drug selection and dosing for patients receiving antithrombotic therapy, and defining the role of companion diagnostics in the use of newer anticoagulant agents.
Contact: Fiona E. Craig, MD, International Clinical Cytometry Society/International Society for Laboratory Hematology
Phone: 412-647-5191
E-mail: craigfe@upmc.edu
back to top
